Skip to main content
Bio-Gate AG logo

Bio-Gate AG — Investor Relations & Filings

Ticker · BIG1 ISIN · DE000BGAG981 LEI · 391200G5LKTIOTZOXP90 F Manufacturing
Open in API
Filings indexed 242 across all filing types
Latest filing 2023-08-29 Earnings Release
Country DE Germany
Listing F BIG1

About Bio-Gate AG

https://www.bio-gate.de/en/

Bio-Gate AG is a provider of innovative technologies and customized solutions for health and hygiene, specializing in antimicrobial and antiviral strategies. The company enhances materials and products by incorporating its unique silver-based technologies, such as MicroSilver BG™. Key applications are concentrated in the medical technology sector, including the coating of medical implants and wound dressings to prevent infections. The company's technologies are also utilized in derma-cosmetics and veterinary care products. Furthermore, Bio-Gate provides solutions for industrial and consumer goods, imparting antimicrobial properties to items like paints, coatings, plastics, and textiles.

Recent filings

Filing Released Lang Actions
Bio-Gate AG: Bio-Gate wachst in der ersten Jahreshalfte 2023 deutlich und bestatigt den Ausblick
Earnings Release Classification · 100% confidence The document is a press release dated August 29, 2023, titled "Bio-Gate wächst in der ersten Jahreshälfte 2023 deutlich und bestätigt den Ausblick". It contains key financial highlights (revenue, EBITDA, equity ratio) for the first half of the year (Erste Jahreshälfte) and confirms the outlook for 2023. The presence of financial figures, period-specific reporting (H1 2023), and the explicit mention of the 'Halbjahresbericht' (Half-Year Report) in the keywords strongly indicate a periodic financial report. Since it covers a period shorter than a year (six months), it classifies as an Interim / Quarterly Report (IR). It is not the full Annual Report (10-K), nor is it merely an announcement of the report's publication (RPA), as it contains substantial summarized financial data and operational review. H1 2023
2023-08-29 German
Bio-Gate AG signs LOI with North American medical device manufacturer for trauma implants
Regulatory Filings Classification · 100% confidence The document is a press release dated July 31, 2023, announcing that Bio-Gate AG signed a Letter of Intent (LOI) with a North American medical device manufacturer regarding the use of their 'HyProtect' coating technology for trauma implants. The keywords 'Incoming Orders/Letter of Intent' and the nature of the announcement (a specific business development/partnership) indicate a corporate news item. This type of announcement, which is not a formal financial report (like 10-K, IR, ER) or a specific regulatory filing (like DIRS, DIV), fits best under the general category for corporate news or regulatory announcements that don't fit elsewhere. Since it is a specific business development announcement, and not a general regulatory filing fallback (RNS), I must check the provided definitions. None of the specific codes (AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, XLSX, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, MDA, NAV, DIV, PSI, DEF 14A, RPA, SHA, POS) perfectly describe a general 'Incoming Order' or 'LOI' announcement. Therefore, the most appropriate fallback category for a significant, non-financial, non-management change corporate announcement is Regulatory Filings (RNS), which serves as the general regulatory announcement/miscellaneous category.
2023-07-31 English
Bio-Gate AG: Thomas Konradt, Annahme von 18.000 Aktienoptionen zum Bezug von je einer Aktie der Bio-Gate AG im Rahmen des Mitarbeiterbeteiligungsprogramms des Emittenten 'Bio-Gate ...
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information regarding a transaction by a member of management ('Vorstand' Thomas Konradt). Section 4 details the transaction type: 'Annahme von 18.000 Aktienoptionen' (Acceptance of 18,000 stock options) as part of an employee participation program. This directly corresponds to the definition of Director's Dealing (insider trades by executives). Therefore, the classification is DIRS.
2023-07-14 German
Bio-Gate AG: Marc Lloret-Grau, Annahme von 27.000 Aktienoptionen zum Bezug von je einer Aktie der Bio-Gate AG im Rahmen des Mitarbeiterbeteiligungsprogramms des Emittenten 'Bio-Gate ...
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information regarding a transaction by a member of the management board ('Vorstand'), Marc Lloret-Grau. Section 2 explicitly mentions the nature of the filing relates to insider transactions ('Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen'). This directly corresponds to the definition of Director's Dealing (DIRS). The document is short and contains the full details, not just an announcement of a report.
2023-07-14 German
Bio-Gate AG: Bio-Gate und OSSIS expandieren mit HyProtectTM-Beschichtungen bei Compassionate Care in weitere internationale Markte
M&A Activity Classification · 99% confidence The document is a press release dated May 22, 2023, announcing a business expansion and partnership update between Bio-Gate AG and OSSIS regarding HyProtectTM coatings. It uses keywords like 'PRESSEINFORMATION', 'EQS-News', and discusses corporate developments (partnership expansion, acquisition by Zimmer Biomet). This type of announcement, which details operational news rather than formal financial results (like 10-K or IR) or specific shareholder actions (like DIV or DVA), typically falls under general corporate news or regulatory announcements. Since it is a news release about a business development and not a formal financial report, it is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a specific reporting period, but here it is clearly a partnership/cooperation update. Given the options, RNS serves as the best general regulatory announcement fallback for non-standard filings, although it shares characteristics with an Earnings Release in terms of being a timely corporate update. However, since it is not explicitly an 'Earnings Release' (ER) focusing on financial figures, RNS is the most appropriate general category for this type of corporate news bulletin distributed via EQS News.
2023-05-22 German
Bio-Gate AG: Bio-Gate bestatigt Vorab-Zahlen 2022 und will 2023 wieder deutlich wachsen
Earnings Release Classification · 100% confidence The document is a press release dated April 28, 2023, titled "Bio-Gate bestätigt Vorab-Zahlen 2022 und will 2023 wieder deutlich wachsen" (Bio-Gate confirms preliminary 2022 figures and aims for significant growth again in 2023). It explicitly discusses the financial results for the fiscal year 2022 (Umsatz/Revenue, Nettoergebnis/Net result) and provides an outlook for 2023. This content structure—summarizing key financial performance metrics for a completed period—is characteristic of an Earnings Release (ER). Although it mentions the full 2022 business report is available elsewhere, this document itself is the initial communication of the results, making it an Earnings Release rather than a Report Publication Announcement (RPA) or the full Annual Report (10-K). The document length (12,300 chars) is substantial enough to contain key figures, not just a brief announcement of publication. FY 2022
2023-04-28 German

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.